Narcolepsy in the pediatric population

Current Neurology and Neuroscience Reports

Volumn 12, Issue 2, 2012, Pages 175-181

  Viorritto, Erick N ^a   Kureshi, Suraiya A ^a   Owens, Judith A ^a  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

Adolescent; Autoimmune disorder; Cataplexy; Child; CNS disorders; Excessive daytime sleepiness; Hypersomnia; Hypocretin; Narcolepsy; Pediatrics; Tribbles

Indexed keywords

ARMODAFINIL; AUTOANTIBODY; FLUOXETINE; INFLUENZA VACCINE; METHYLPHENIDATE; MODAFINIL; ORAL CONTRACEPTIVE AGENT; OREXIN; OXYBATE SODIUM; TRIBBLES HOMOLOGUE 2 AUTOANTIBODY; UNCLASSIFIED DRUG; VENLAFAXINE;

ALLELE; ANTIBODY TITER; ANXIETY; ARTICLE; AUTOIMMUNE DISEASE; CATAPLEXY; CLINICAL FEATURE; DAYTIME SOMNOLENCE; DIAGNOSTIC PROCEDURE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; DIZZINESS; DRUG INDUCED HEADACHE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EVENING DOSAGE; EXCESSIVE DAYTIME SOMNOLENCE; HAPLOTYPE; HEADACHE; HUMAN; HYPNAGOGIC HALLUCINATION; IMMUNOPATHOGENESIS; INFLUENZA VACCINATION; INSOMNIA; MULTIPLE SLEEP LATENCY TEST; NARCOLEPSY; NAUSEA; NONHUMAN; PARASOMNIA; PATHOPHYSIOLOGY; PEDIATRICS; POLYSOMNOGRAPHY; PROTEIN CEREBROSPINAL FLUID LEVEL; REBOUND; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; SOMNOLENCE; STEVENS JOHNSON SYNDROME; SUICIDAL IDEATION;

ANTIBODIES; HLA-DQ BETA-CHAINS; HUMANS; HYPOTHALAMUS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NARCOLEPSY; NEUROIMAGING; NEURONS; NEUROPEPTIDES; PEDIATRICS;

EID: 84861228031     PISSN: 15284042     EISSN: 15346293     Source Type: Journal    
DOI: 10.1007/s11910-011-0246-3     Document Type: Article

References (41)

1. American Academy of Sleep Medicine. International classification of sleep disorders, revised: Diagnostic and coding manual. Chicago, Illinois: American Academy of Sleep Medicine; 2001.
2. Ahmed I, Thorpy M: Clinical features, diagnosis and treatment of narcolepsy. Clin Chest Med 2010, 31:371-381.
3. McCarty D. A case of narcolepsy with strictly unilateral cataplexy. J Clin Sleep. 2010;6:75-6.
4. Overeem S, van Nues S, van der Zande W, et al. The clinical features of cataplexy: A questionnaire study in narcolepsy patients with and without hypocretin-1 deficiency. Sleep Med. 2011;12:12-8.
5. Bayard S, Abril B, Yu H, et al. Decision making in narcolepsy with cataplexy. Sleep. 2011;34:99-104.
6. Delazer M, Hogl B, Zamarian L, et al. Executive functions, information sampling, and decision making in narcolepsy with cataplexy. Neuropsych. 2011;25:477-87.
7. Drooglever Fortuyn H, Lappenshaar M, Furer J, et al. Anxiety and mood disorders in narcolepsy: a case-control study. Gen Hosp Psych. 2010;32:49-56.
8. Bhat S, Galang R. Narcolepsy presenting as schizophrenia [letter]. Am J Psychiatry. 2002;159:1245.
9. Perriol M, Lamblin M, Poirot I, et al. Childhood-onset narcolepsy, obesity, and puberty in four consecutive children: a close temporal link. J Ped Endocrin & Metabol. 2010;23:257-65.
10. Peraita-Adrados R, Garcia-Penas J, Ruiz-Falco L, et al.: Clinical, polysomnographic and laboratory characteristics of narcolepsycataplexy in a sample of children and adolescents. Sleep Med 2011, 12:24-27.
11. Kanbayashi T, Sagawa Y, Takemura F, et al.: The patholophysiologic basis of secondary narcolepsy and hypersomnia. Curr Neurol Neurosci Rep 2011, 11:235-241.
12. Pizza F, Vandi S, Detto S, et al. Different sleep onset criteria at the multiple sleep latency test (MSLT): an additional marker to differentiate central nervous system (CNS) hypersomnias. J Sleep Res. 2011;20:250-6.
13. Hor H, Kutalik Z, Dauviliers Y, et al. Genome-wide association study identifies new HLA class II haplotypes strongly protective against narcolepsy. Nat Genet. 2010;42:786-9.
14. Molari A, Carcassi C. HLA and narcolepsy-cataplexy in the Sardinian population [letter]. J Sleep Res. 2010;19:624-5.
15. Watson N, Ton T, Koepsell T, et al. Does narcolepsy symptom severity vary according to HLA-DQB1*0602 allele status? Sleep. 2010;33:29-35.
16. Goel N, Banks S, Mignot E, Dinges D. DQB1*0602 predicts interindividual differences in physiologic sleep, sleepiness, and fatigue. Neurology. 2010;75:1509-19.
17. Nakamura M, Kanbayashi T, Sugiura T, Inoue Y. Relationship between clinical characteristics of narcolepsy and CSF orexin-A levels. J Sleep Res. 2011;20:45-9.
18. Knudsen S, Jennum P, Alving J, et al. Validation of the ICSD-2 criteria for CSF hypocretin-1 measurements in the diagnosis of narcolepsy in the Danish population. Sleep. 2010;33:169-76.
19. Cvetkovic-Lopez V, Bayer L, Dorsaz S, et al.: Elevated Tribbles homolog 2-specific antibody levels in narcolepsy patients. J Clin Investigation 2010, 120:713-719.
20. Kawashima M, Lin L, Tanaka S, et al.: Anti-Tribbles homolog 2 (TRIB2) autoantibodies in narcolepsy are associated with recent onset cataplexy. Sleep 2010, 33:869-874.
21. Toyoda H, Tanaka S, Miyagawa T, et al.: Anti-Tribbles homolog 2 autoantibodies in Japanese patients with narcolepsy. Sleep 2010, 33:875-878.
22. Lim A, Scammell T: The trouble with Tribbles: Do antibodies against TRIB2 cause narcolepsy? [commentary] Sleep 2010, 33:857-858.
23. Dauvilliers Y, Montplaisir J, Cochen V, et al. Post-H1N1 narcolepsy-cataplexy [letter]. Sleep. 2010;33:1428-30.
24. Morrison I, Buskova J, Nevsimalova S, et al. Diagnosing narcolepsy with cataplexy on history alone: challenging the International Classification of Sleep Disorders (ICSD-2) criteria. Eur J Neurology. 2011;18:1017-20.
25. Doherty L, Crowe C, Sweeney B. National narcolepsy survey. Ir Med J. 2010;103:112-3.
26. Nevsimalova S, Jara C, Prihodova I, et al. Clinical featuers of childhood narcolepsy: can cataplexy be foretold? Eur J Ped Neurol. 2011;15:320-5.
27. Han F, Lin L, Li J, et al. Presentations of primary hypersomnia in Chinese children. Sleep. 2011;34:627-32.
28. Plazzi G, Tonon C, Rubbioli G, et al. Narcolepsy with cataplexy associated with holoprosencephaly misdiagnosed as epileptic drop attacks [letter]. Mov Disord. 2010;25:788-90.
29. Bican A, Bora I, Algin O, Hakyemez B. Neuroimaging in narcolepsy. Sleep Med. 2010;11:225-6.
30. Dauvilliers Y, Comte F, Bayard S, et al. A brain PET study in patients with narcolepsy-cataplexy. J Neurol Neurosurg Psychiatry. 2010;81:344-8.
31. Cao M: Advances in narcolepsy. Med Clin N Am 2010, 94:541-555.
32. Black J, Pardi D, Hornfeldt C, Inhaber N. The nightly use of sodium oxybate is associated with a reduction in nocturnal sleep disruption: a double-blind, placebo-controlled study in patients with narcolepsy. J Clin Sleep Med. 2010;6:596-602.
33. Alshaikh M, Sharif M. Long-term follow-up of patients with narcolepsy-cataplexy treated with sodium oxybate (Xyrem). Clin Neuropharm. 2011;34:1-4.
34. Knudsen S, Mikkelsen J, Bang B, et al.: Intravenous immunoglobulin treatment and screening for hypocretin neuron-specific autoantibodies in recent onset childhood narcolepsy with cataplexy. Neuropediatrics 2010, 41:217-222.
35. Lecendreux M, Maret S, Bassetti C, et al. Clinical efficacy of highdose intravenous immunoglobulins near the onset of narcolepsy in a 10-year-old boy [letter]. J Sleep Res. 2003;12:347-8. (Pubitemid 38010443)
36. Dauvilliers Y, Carlander B, Rivier F, et al. Successful management of cataplexy with intravenous immunoglobulins at narcolepsy onset. Ann Neurol. 2004;56:905-8. (Pubitemid 39578460)
37. Plazzi G, Poli F, Franceschini C, et al. Intravenous high-dose immunoglobulin treatment in recent onset childhood narcolepsy with cataplexy. J Neurol. 2008;255:1549-54.
38. Dauvilliers Y. Follow-up of four narcolepsy patients treated with intravenous immunoglobulins [letter]. Ann Neurol. 2006;60:153.
39. Fronczek R, Verschuuren J, Lammers GJ. Response to intravenous immunoglobulins and placebo in patient with narcolepsy with cataplexy [letter]. J Neurol. 2007;254:1607-8. (Pubitemid 350159905)
40. Dauvilliers Y, Abril B, Mas E, et al. Normalization of hypocretin-1 in narcolepsy after intravenous immunoglobulin treatment. Neurology. 2009;73:1333-4.
41. American Academy of Sleep Medicine. International classification of sleep disorders, 2nd ed.: diagnostic and coding manual. Westchester, IL: American Academy of Sleep Medicine; 2005.